Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction

Journal of Sexual Medicine

Volumn 8, Issue 3, 2011, Pages 851-864

  Kamenov, Zdravko Asenov ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Diabetic Erectile Dysfunction; Diabetic Neuropathy; First Intake of Tadalafil and Vardenafil; IIEF SEP2 SEP3 GAQ; PDE5 Inhibitors

Indexed keywords

TADALAFIL; VARDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIABETIC ERECTILE DYSFUNCTION; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; GLOBAL ASSESSMENT QUESTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SEXUAL ENCOUNTER PROFILE QUESTION 2; SEXUAL ENCOUNTER PROFILE QUESTION 3;

EID: 79951970024     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02148.x     Document Type: Article

References (59)

1. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980;18:279-83.
2. Fedele D, Coscelli C, Santeusanio F, Bortolotti, A, Chatenoud L, Colli E, Landoni M, Parazzini F. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 1998;21:1973-7.
3. Siu SC, Lo SK, Wong KW, Ip KM, Wong YS. Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabet Med 2001;18:732-8.
4. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25:1458-63.
5. Vickers MA, Wright EA. Erectile dysfunction in the patient with diabetes mellitus. Am J Manag Care 2004;10(1 suppl):S3-11.
6. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7, 689 patients with diabetes or hypertension, or both. Urology 2004;64:1196-201.
7. Sasaki H, Yamasaki H, Ogawa K, Nanjo K, Kawamori R, Iwamoto Y, Katayama S, Shirai M. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005;70:81-9.
8. Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med 2008;5:2125-34.
9. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-47.
10. Kamenov Z, Christov V, Yankova T. Erectile dysfunction in diabetic men-Linked more to microangiopathic complications and neuropathy than to macroangiopathic disturbances. J Mens Health 2007;4:64-73.
11. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. J Urol 2003;170(2 Pt 2):S35-8.
12. Snow JK. Erectile dysfunction in patients with diabetes mellitus-Advances in treatment with phosphodiesterase type 5 inhibitors. Br J Diabetes Vasc Dis 2002;2:282-7.
13. Schulman CC, Shen W, Stothard DR, Schmitt H. Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology 2004;64:783-8.
14. Valiquette L, Young JM, Moncada I, Porst H, Vézina JG, Stancil BN, Edmunds K, Montorsi F; Vardenafil Study Group. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005;80:1291-7.
15. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the UK hospital clinic population. Diabetologia 1993;36:150-6.
16. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile function. Urology 1997;49:822-30.
17. Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004;64:2667-88.
18. Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, Smith PM, Wilkins HJ, Pommerville P, Vardenafil Study Group. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: A randomized, double-blind, placebo-controlled study. Eur Urol 2006;50:1086-94.
19. Martín-Morales A, Gutiérrez Hernández PR, Meijide Rico F, Arrondo Arrondo JL, Turbí Disla C. Effectiveness and treatment satisfaction in patients with erectile dysfunction in Spain: EDOS study. Actas Urol Esp 2010;34:356-64.
20. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y, Warner MR, Beardsworth A. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61.
21. Eardley I, Rosen R, Fisher WA, Niederberger C, Sand M. Attitudes toward treatment of erectile dysfunction: Results from the MALES study. Eur Urol Suppl 2003;2:97.Abstr. 377.
22. Meuleman EJ, Eardley I, Rosen R, Fisher W, Niederberger C, Sand M. Attitudes toward treatment of erectile dysfunction: Results from the MALES (Men's Attitudes toward Life Events and Sexuality) study. Presented at: Annual Meeting of the Asian Pacific Society of Sexual and Impotence Research; Cebu, Philippines; October 1-4, 2003.
23. Eardley I, Fisher W, Rosen RC, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality study: The influence of diabetes on self-reported erectile function, attitudes and treatment-seeking patterns in men with erectile dysfunction. Int J Clin Pract 2007;61:1446-53.
24. Edmonds ME, Foster AV. Reduction of major amputations in the diabetic ischaemic foot: A strategy to "take control" with conservative care as well as revascularization. Vasa 2001;58:6-14.
25. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-6.
26. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004;93:1276-81.
27. Carson CC, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C; Trial Evaluating the Activity of Tadalafil for Erectile Dysfunction-United States (TREATED-US) Study Group. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005;65:353-9.
28. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64.
29. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23.
30. Montorsi F, Hellstrom WJ, Valiquette L, Bastuba M, Collins O, Taylor T, Thibonnier M, Homering M, Eardley I; North American and European Vardenafil Groups. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004;64:1187-95.
31. Incrocci L, Slob AK, Hop WC. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: An open-label extension of a blinded trial. Urology 2007;70:1190-3.
32. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300.
33. Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351-9.
34. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP 3rd, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebocontrolled study in the US. Int J Impot Res 2007;19:95-103.
35. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25:138-46.
36. Porst H, Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR. Long-term safety and efficacy of tadalafil 5mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:2160-9.
37. Buvat J, van Ahlen H, Schmitt H, Chan M, Kuepfer C, Varanese L. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med 2006;3:512-20.
38. Lewis RW, Sadovsky R, Eardley I, O'Leary M, Seftel A, Wang WC, Shen W, Walker DJ, Wong DG, Ahuja S. The efficacy of tadalafil in clinical populations. J Sex Med 2005;2:517-31.
39. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9.
40. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H, European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol 2004;45:634-41.
41. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T, Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
42. Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003;170(Pt 1):1278-83.
43. Potempa AJ, Ulbrich E, Bernard I, Beneke M, Vardenafil Study Group. Efficacy of vardenafil in men with erectile dysfunction: A flexible-dose community practice study. Eur Urol 2004;46:73-9.
44. Eardley I, Lee JC, Shabsigh R, Dean J, Maggi M, Neuser D, Norenberg C. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med 2010;7(Pt 1):244-55.
45. van Ahlen H, Zumbé J, Stauch K, Hanisch JU. The Real-Life Safety and Efficacy of Vardenafil (REALISE) Study: Results in Men from Europe and Overseas with Erectile Dysfunction and Cardiovascular or Metabolic Conditions. J Sex Med 2010;7:3161-9.
46. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
47. Boulton AJM, Selam J-L, Sweeney M, Ziegler D. Sildenafil for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44:1296-301.
48. Saenz de Tejada I, Emmick J, Anglin G, Knight JR, Emmick JT. The effect of IC351 taken as needed for treatment of erectile dysfunction in men with diabetes. Eur Urol 2001;39:16, abstr. 55.
49. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I; Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: A randomized, double-blind, pooled crossover study. J Sex Med 2006;3:1037-49.
50. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M; Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-17.
51. Traish A, Kim N. The physiological role of androgens in penile erection: Regulation of corpus cavernosum structure and function. J Sex Med 2005;2:759-70.
52. Shabsigh R, Rajfer J, Aversa A, Traish AM, Yassin A, Kalinchenko SY, Buvat J. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60:1087-92.
53. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-9.
54. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002;168:615-20.
55. Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980;243:750-5.
56. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9.
57. Kalinchenko S, Zemlyanoy A, Gooren LJ. Improvement of the diabetic foot upon testosterone administration to hypogonadal men with peripheral arterial disease. Report of three cases. Cardiovasc Diabetol 2009;8:197.
58. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
59. Park HJ, Choi HK, Ahn TY, Park JK, Chung WS, Lee SW, Kim SW, Hyun JS, Park NC. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: A multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med 2010;7:2842-50.